Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $32.17 Consensus Target Price from Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have received a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the company, MarketBeat reports. Five analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $32.1667.

Several analysts have commented on the stock. Oppenheimer cut shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 7th. Zacks Research cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Friday, March 27th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Finally, Robert W. Baird cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th.

Institutional Trading of Catalyst Pharmaceuticals

A number of large investors have recently made changes to their positions in CPRX. Rothschild Investment LLC increased its position in shares of Catalyst Pharmaceuticals by 1,085.7% in the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 1,520 shares in the last quarter. Advisory Services Network LLC bought a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at $39,000. Quarry LP bought a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at $40,000. Clearstead Advisors LLC increased its position in shares of Catalyst Pharmaceuticals by 192.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 1,167 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its position in shares of Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 630 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $31.26 on Friday. The firm has a fifty day moving average of $26.81 and a two-hundred day moving average of $24.68. The stock has a market capitalization of $3.83 billion, a price-to-earnings ratio of 17.97, a PEG ratio of 0.91 and a beta of 0.72. Catalyst Pharmaceuticals has a 52 week low of $19.05 and a 52 week high of $32.56.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).